| Factor Information | |
|---|---|
| Data ID | 2839 |
| Factor | Fibrosis Index--Subgroup: Other congenital |
| Description | Values were highest in patients with a systemic RV (35.0±5.8%; P<0.001) and those who were cyanotic (33.7±5.6%; P<0.001). |
| Biomarker | NA |
| Classification | A6 (clinical factor - other) |
| Association | |
|---|---|
| Application | prognosis |
| Objective | We sought to apply this method for detection and quantification of fibrosis in patients with ACHD. |
| p Value | 0.002 |
| Conclusion | Values were highest in patients with a systemic RV (35.0±5.8%; P<0.001) and those who were cyanotic (33.7±5.6%; P<0.001). |
| Risk Factor | unknown |
| CHD Type | |
|---|---|
| ID | 148 |
| CHD Type | NA |
| CHD Subtype | NA |
| Reference | |
|---|---|
| PMID | 20855860 |
| Year | 2010 |
| Title | Quantification of diffuse myocardial fibrosis and its association with myocardial dysfunction in congenital heart disease |
| Sample | ||
|---|---|---|
| Population | Adults | |
| Source | MRI | |
| Region | Oregon, USA | |
| Method | patients with ACHD (n=50) were studied with cardiac MRI to quantify systemic ventricular volume and function and diffuse fibrosis. | |
| Race | North America | |
| Disease History | N/A | |
| Treatment History | N/A | |
| Group | Other congenital(Treatment) | Normal control(Control) |
| Number | 12 | 14 |
| Age | 32.9±12.4 years | 37.7±11.9 years |
| Gender (Male: Female) | 9:3 | 8:6 |
| Marker Level | 31.4±3.2%(min-max: 26.2%–36.5%) | 24.8±2.0% (min-max: 21.6%–28.1%) |
